<DOC>
	<DOCNO>NCT00439881</DOCNO>
	<brief_summary>SB-681323 inhibits action enzyme know contribute inflammation see condition Chronic Obstructive Pulmonary Disease Rheumatoid Arthritis . This study explore safety drug blood level give intravenous form healthy human volunteer .</brief_summary>
	<brief_title>A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>A healthy male age 25 55 year , inclusive , time screen . Body weight = 60 kg Body Mass Index within range 19 32 kg/m2 inclusive . Must give informed consent sign study consent form prior take part study procedure . Have significant abnormality clinical examination . Show abnormality haematology , clinical chemistry urinalysis examination prestudy medical examination . Demonstrate clinically normal 12lead ECG screen Liver function test within reference range screening ( ALT , AST , ALP , GT bilirubin ) Do show evidence prestudy HIV hepatitis B C screen Do show positive prestudy urine drug screen Taken prescription overthecounter medication within 5 day ( 5 half life , whichever long ) first dose day , unless investigator confirm introduce additional risk interfere study procedure outcome . Show history evidence drug alcohol abuse . Show history increase liver function test ( ALT , AST , bilirubin ) upper limit normal ( ULN ) past 6 month ( know ) . Demonstrate history regular alcohol consumption exceed average weekly intake &gt; 21 unit ( average daily intake great 3 unit ) . 1 unit equivalent halfpint ( 284mL ) beer/lager ; 25mL measure spirit 125mL wine . Have history presence medically significant disease , disorder would introduce additional risk interfere study procedure outcome . In particular , gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . Exposure prior first dose day 3 new medicinal entity within 12 month participate study new medicinal entity within 3 month study within 2 month . If participation study result subject donate 450 mL blood within 3 month period . On physical examination subject observe poor venous access . An unwillingness subject abstain sexual intercourse woman ; unwillingness subject use condom/spermicide addition female partner use another form contraception woman could become pregnant time first dose investigational product completion followup procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>inflammation ,</keyword>
	<keyword>intravenous ,</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ,</keyword>
	<keyword>P38 inhibitor</keyword>
	<keyword>SB-681323 ,</keyword>
	<keyword>rheumatoid arthritis ,</keyword>
</DOC>